Adalimumab (Yuflyma)
Celltrion Healthcare
Description
Adalimumab binds specifically to TNF and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors.
Indications
Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.
Price
Pre-filled injection, £633.60, 20-60mg
More on: Systemic psoriasis treatments